FDA approves NexMed OTC anti-fungal drug
Tolnaftate, the active ingredient of Tolnaftate-D, is already approved as a treatment of jock itch, athlete’s foot and ringworm. Apricus Biosciences wholly owned subsidiary NexMed’s Tolnaftate-D uses NexACT
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).
Vecuronium bromide for injection is indicated for the patients with myasthenia gravis or the myasthenic (Eaton-Lambert) syndrome (muscle weakness/fatigue). The injection features Sagent’s PreventIV Measures packaging and labeling